Compare MLSS & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MLSS | TVGN |
|---|---|---|
| Founded | 1989 | 2020 |
| Country | United States | United States |
| Employees | N/A | 18 |
| Industry | Industrial Specialties | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.1M | 21.3M |
| IPO Year | 1996 | N/A |
| Metric | MLSS | TVGN |
|---|---|---|
| Price | $0.41 | $4.06 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $1.00 | N/A |
| AVG Volume (30 Days) | ★ 170.2K | 18.6K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,973,982.00 | N/A |
| Revenue This Year | $12.64 | N/A |
| Revenue Next Year | $8.99 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.99 | N/A |
| 52 Week Low | $0.22 | $0.14 |
| 52 Week High | $0.68 | $12.03 |
| Indicator | MLSS | TVGN |
|---|---|---|
| Relative Strength Index (RSI) | 59.36 | 29.60 |
| Support Level | $0.24 | $0.30 |
| Resistance Level | $0.44 | $5.64 |
| Average True Range (ATR) | 0.03 | 0.47 |
| MACD | 0.01 | -0.14 |
| Stochastic Oscillator | 66.86 | 12.99 |
Milestone Scientific Inc develops and commercializes proprietary computer-controlled drug delivery systems designed to enhance the safety, precision, and patient experience associated with subcutaneous injections and fluid aspiration procedures. The company's core technology platform, Dynamic Pressure Sensing (DPS) Technology, controls flow rate and measures pressure at the needle tip in real time. DPS Technology is incorporated into both the company's dental and medical products and supports clinical applications, including local anesthesia delivery, epidural space identification in regional anesthesia procedures, and intra-articular joint injections. It operates in two segments: Dental, which markets and sells its dental products, and Medical, markets and sells its medical products.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The first clinical product of ExacTcell, TVGN 489, is initially being developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic, lingering symptoms of the disease (Long COVID). Viruses, including COVID-19, hijack cellular machinery to transform infected cells into virus production plants.